Kohlberg Kravis Roberts & Co. L.P. Coherus Bio Sciences, Inc. Transaction History
Kohlberg Kravis Roberts & Co. L.P.
- $2.53 Billion
- Q2 2025
A detailed history of Kohlberg Kravis Roberts & Co. L.P. transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Kohlberg Kravis Roberts & Co. L.P. holds 3,036,076 shares of CHRS stock, worth $4.16 Million. This represents 0.09% of its overall portfolio holdings.
Number of Shares
3,036,076
Previous 3,036,076
-0.0%
Holding current value
$4.16 Million
Previous $2.46 Million
9.88%
% of portfolio
0.09%
Previous 0.11%
Shares
2 transactions
Others Institutions Holding CHRS
# of Institutions
119Shares Held
58.2MCall Options Held
89.3KPut Options Held
31K-
Black Rock Inc. New York, NY11.8MShares$16.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.6MShares$14.5 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA5.1MShares$6.98 Million0.22% of portfolio
-
Geode Capital Management, LLC Boston, MA2.68MShares$3.67 Million0.0% of portfolio
-
Cm Management, LLC2.25MShares$3.08 Million1.68% of portfolio
About Coherus BioSciences, Inc.
- Ticker CHRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,724,600
- Market Cap $106M
- Description
- Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...